Liraglutide

Key Benefits#

• Promotes weight loss (5–10% average)
• Reduces appetite and caloric intake
• Improves blood glucose control (HbA1c reduction)
• Reduces cardiovascular events in T2DM (LEADER trial)
• Slows gastric emptying
• FDA-approved for T2DM and chronic weight management
• Cardioprotective effects shown in clinical trials
• May improve fatty liver (NAFLD/NASH)

Mechanism of Action#

Liraglutide is a GLP-1 analog with 97% sequence homology to human GLP-1, modified with a fatty acid chain that enables binding to serum albumin, extending half-life from 2 minutes (native GLP-1) to ~13 hours. It activates GLP-1 receptors in the pancreas (stimulating glucose-dependent insulin secretion, inhibiting glucagon), hypothalamus (suppressing appetite, increasing satiety signals), gut (slowing gastric emptying), and cardiovascular system (cardioprotective effects). Unlike native GLP-1, it resists DPP-4 enzymatic degradation.

Dosing Protocols#

Side Effects#

• Nausea (very common, especially initially)
• Vomiting
• Diarrhea or constipation
• Decreased appetite
• Hypoglycemia (when combined with insulin or sulfonylureas)
• Injection site reactions
• Rare: pancreatitis
• Rare: thyroid C-cell tumors (animal data)
• Rare: gallbladder issues

Contraindications#

Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2. Use with caution in pancreatitis history. Not for T1DM. Pregnancy: avoid (Category C).

Storage#

Store unopened pens at 2–8°C (refrigerator). In-use pens: store at room temperature (up to 30°C) for up to 30 days. Do not freeze.

Featured In Stacks#

1. 1.
   Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction

   Li Y, Liu W, Wang Y, Wang B, Xu X, Li B et al. · Diabetes, obesity & metabolism · 2026PubMed Verified

2. 2.
   Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study

   Guo M, Chen S, Dong H, Cai M, Guo M, Cheng H · Naunyn-Schmiedeberg's archives of pharmacology · 2026PubMed Verified

3. 3.
   Intra-articular GLP-1 analogues: a new disease-modifying strategy for osteoarthritis?

   Berenbaum F · Joint bone spine · 2026PubMed Verified

4. 4.
   Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System

   Seijas-Amigo J, Salgado-Barreira Á, Rodriguez-Penas D, Cardeso-Paredes B, Ribeiro-Ferreiro M, Rodriguez-Mañero M et al. · International journal of clinical pharmacy · 2026PubMed Verified

5. 5.
   Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis

   Yang Y, Cheng X, Chen S, Xie J, Chen G, Li L et al. · International journal of surgery (London, England) · 2026PubMed Verified

6. 6.
   Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study

   Cheng H, Jiang X, Zhu X, Zhu X, Li C, Cao M et al. · Obesity (Silver Spring, Md.) · 2026PubMed Verified

7. 7.
   Weight regain after bariatric surgery: A framework for management

   Niedbala CG · JAAPA : official journal of the American Academy of Physician Assistants · 2026ReviewPubMed Verified

8. 8.
   Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation

   Xu Y, Huang T, Zhang Y, Ji D, Tuttle KR, Carrero JJ et al. · Circulation · 2026PubMed Verified

9. 9.
   Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes

   Almukhadeb E, Nagshabandi KN, Alshehri N, Alosaimi K, Almusa HA, Almudimeegh A · International journal of dermatology · 2026ReviewPubMed Verified

10. 10.
    Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients

    Choi WS, Song MK, Seo M, Woo YS, Bahk WM · Therapeutic advances in psychopharmacology · 2026PubMed Verified

11. 11.
    Hyperglycemia promotes maladaptive Dectin-1 signaling and impairs skin antifungal host defense

    Reyna DE, Davis E, Salina ACG, Blackman A, Martinez-Barricarte R, Doran A et al. · bioRxiv : the preprint server for biology · 2026PubMed Verified

12. 12.
    Mo-Rubbing abdominal improves metabolic homeostasis in type 2 diabetes mellitus mice via a jejunum-specific GLP1-dependent mechanism

    Zhang Z, Gan L, Camille C, He X, Li L, Chen Y et al. · Diabetes, obesity & metabolism · 2026PubMed Verified

13. 13.
    Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials

    Chiappa GR, Santos PCN, Cavalcante DVS, Sá Filho AS, Prado N, Lombardo KM et al. · Diabetes, obesity & metabolism · 2026ReviewPubMed Verified

14. 14.
    Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment

    Tentolouris A, Koufakis T, Fousteris E · Current obesity reports · 2026ReviewPubMed Verified

15. 15.
    The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis

    Hertzer LA, Siegel RM, Kharofa RY, Stackpole KM, Mahabee-Gittens EM · Childhood obesity (Print) · 2026Meta-AnalysisPubMed Verified

16. 16.
    Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist

    Van Laren J, Friesleben C, Gershovich O, Helm L, Patel RJ, Delate T · Diabetes, obesity & metabolism · 2026PubMed Verified

17. 17.
    Synergistic role of exercise and liraglutide in modulating GLP-1R binding and metabolic outcomes: a combined computational and experimental study

    Razmi S, Moshtaghie AA, Seyedabadi M, Hashem N, Akbarzadeh S · 3 Biotech · 2026PubMed Verified

18. 18.
    Challenges in the management of obesity

    Smith BL, May A, Lalani F, Hasham S, Presnell AA · Journal of clinical lipidology · 2026ReviewPubMed Verified

19. 19.
    GLP-1 agonists and the gut microbiome: A bidirectional relationship

    Kamath S, Chan NSL, Joyce P · British journal of clinical pharmacology · 2026ReviewPubMed Verified

20. 20.
    Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis

    Belančić A, Antza C, Poutachidis A, Palaska S, Gkrinia EMM, Faour AK et al. · British journal of clinical pharmacology · 2026PubMed Verified

21. 21.
    GLP-1 and the cardiovascular system

    Kahles F, Birkenfeld AL, Marx N · The Journal of clinical investigation · 2026ReviewPubMed Verified

22. 22.
    Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov

    Patil S, Jha N, Jha MK · Addictive behaviors reports · 2026PubMed Verified

23. 23.
    Pediatric Obesity: Diagnostic and Therapeutic Approaches in the Context of International Guidelines With a Focus on Polish Practice

    Łuczak PM, Perediatkiewicz J, Liszka P, Puchalski K, Patrzykąt KM, Olejnik-Chlewicka KM et al. · Cureus · 2026ReviewPubMed Verified

24. 24.
    Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study

    Sánchez-García D, Luna-Garza Y, Saavedra-Castillo E, Gómez-Martínez G, Diaz-Sallas M, Ortega-Valdez AC et al. · Diabetic medicine : a journal of the British Diabetic Association · 2026PubMed Verified

25. 25.
    Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial

    Bai S, Wei M, Wu Y, Zhu X, Wang Z, Wang Y et al. · BMJ open · 2026Clinical TrialPubMed Verified

26. 26.
    Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use

    Menkü Özdemir FD, Uzun H · Annals of plastic surgery · 2026PubMed Verified

27. 27.
    Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study

    Mai T · Medicine · 2026PubMed Verified

28. 28.
    Anatomical evidence links the stomach to the central amygdala, a region responsive to local GLP-1R agonist induced feeding and nausea-like behaviors in male mice

    Yang H, Yu W, Gao Y, Wang J, Xu S · Frontiers in endocrinology · 2026PubMed Verified

29. 29.
    The Effect of GLP-1 Receptor Agonists on Autophagy: Insights Gathered from Research Evaluating Neurodegenerative Disorders With These Agents

    Sioufi MC, Heroiu I, Wong S, Le GH, Dri CE, Zheng YJ et al. · Acta neuropsychiatrica · 2026ReviewPubMed Verified

30. 30.
    GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites

    Gong B, Shi Z, Qi J, Wang F, Chen G, Su H · Nutrients · 2026PubMed Verified

31. 31.
    Predicting Weight Outcomes From Obesity Medications in a Paediatric Population

    Mottalib MM, Beheshti R, Viswanathan K, Bunnell HT, Phan TT · Pediatric obesity · 2026PubMed Verified

32. 32.
    The promoting roles of GLP1R and GIPR in stemness maintenance and multiple lineage-specific differentiation of PDLSCs

    Shen Y, Zhang M, Yang T, Wu Y, Qiu Y, Zhang L et al. · Cellular & molecular biology letters · 2026PubMed Verified

33. 33.
    Liraglutide attenuates aluminum chloride-induced Alzheimer's disease in rats by modulating the oxLDL/LPA/LPAR1 pathway

    Abo El-Magd NF, Ramadan NM, Eraky SM · Communications biology · 2026PubMed Verified

34. 34.
    Current Practices and Challenges in Pediatric Obesity Management (POM): A Nationwide Survey of Physicians in Korea

    Lee Y, Shin M, Chung S, Jung J, Sul AR, Hong YH · Journal of Korean medical science · 2026PubMed Verified

35. 35.
    Systemic Pharmacokinetic Principles of Therapeutic Peptides

    Nordell P, Jansson-Löfmark R, Gennemark P · Clinical pharmacokinetics · 2026PubMed Verified

36. 36.
    Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents

    Shevchouk O, Edvardsson CE, Ericson M, Blid Sköldheden S, Zhang Q, Dreher Nabinger D et al. · Behavioural brain research · 2026PubMed Verified

37. 37.
    Injectable Schiff base-engineered hydrogel for spatiotemporal liraglutide delivery orchestrates diabetic periodontitis regression via multimodal microenvironment reprogramming

    Li J, Li R, Zhou Y, Zheng S, Xu J, Zhu J et al. · Journal of controlled release : official journal of the Controlled Release Society · 2026PubMed Verified

38. 38.
    In brief: Removal of suicidality warning from GLP-1 Agonists for weight management

    The Medical letter on drugs and therapeutics · 2026PubMed Verified

39. 39.
    Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial

    Fang W, Li Z, Xu J, Zhao J, Zhu H, Wang H · Frontiers in endocrinology · 2025Clinical TrialPubMed Verified

40. 40.
    Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis

    Wang Y, Feng L, Wang Y, Li B, Liang N, Song X et al. · Renal failure · 2026Meta-AnalysisPubMed Verified

41. 41.
    GLP-1 receptor agonist suppresses fatty infiltration while improving range of motion and electromyographic function in a chronic rotator cuff tear rat model

    Yoon JP, Park SJ, Kim DH, Lee HJ, Kim JY, Pham DT et al. · Journal of shoulder and elbow surgery · 2026PubMed Verified

42. 42.
    Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity-A Meta-Analysis

    Rego de Figueiredo I, Simas FS, Ghiletchi A, Oliveira Torres J, Silva-Nunes J · Obesity (Silver Spring, Md.) · 2026ReviewPubMed Verified

43. 43.
    Algorithm-Based Common Microcirculatory Framework for Monitoring and Visualizing the Integrated Pancreatic Microcirculation in Type 2 Diabetes Mellitus Mice

    Li Y, Wang Y, Wang B, Liu W, Xu M, Zhang X et al. · Journal of diabetes · 2026PubMed Verified

44. 44.
    Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice

    Oh EY, Suh SH, Byeon S, Lee J, Lee YH, Choi SK · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026PubMed Verified

45. 45.
    Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder

    Fakhoury B, Sierra L, Rama K, Jahagirdar V, Díaz LA, Arab JP · JAMA network open · 2025PubMed Verified

46. 46.
    Management of Obesity in Psoriasis Consultations

    Nicolau J, López-Ferrer A, de la Cueva P · Dermatology and therapy · 2026PubMed Verified

47. 47.
    Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics

    AlTaib HN, AlAqeel R, Arafat AA, Kunnathodi F, AlShaikh A, AlOtaibi HF · PloS one · 2026PubMed Verified

48. 48.
    Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching

    Yuan Z, Jeffcoat CH, Ali SR, Sena AG, Schuemie MJ, Ryan PB et al. · PloS one · 2026PubMed Verified

49. 49.
    Liraglutide prevents lupus-associated diffuse alveolar hemorrhage via inhibiting lymphocyte infiltration and promoting macrophage M2 polarization

    Jiang L, He L, Li D, Luo X, Yang M, Wu H et al. · Journal of translational autoimmunity · 2026PubMed Verified

50. 50.
    Morphology-driven zinc oxide biointeractive carriers with biological barrier modulating effects for pulmonary delivery of liraglutide

    Jeong JH, Han CS, Kang JH, Kim DW, Park CW · Journal of nanobiotechnology · 2026PubMed Verified